Biogen is planning to file for U.S. regulatory approval for its Alzheimer's treatment after fresh analysis of its clinical trial showed promise, the drugmaker said. CNBC's Meg Tirrell Reports.
The PRIME study of the immunotherapy agent aducanumab for Alzheimer’s disease made big news recently. An investigator in ongoing phase 3 trials of the agent sizes up PRIME and looks to what’s next.
Biogen Will Take Alzheimer's Therapy to FDA, Reviving HopeBiogen Inc. will ask U.S. drug regulators to approve the company’s experimental Alzheimer’s therapy, reviving the nearly abandoned treatment after a new analysis of data from two failed clinical trials showed promising
Dr. Ronald Petersen, director of the Alzheimer's Disease Research Center at Mayo Clinic, says aducanumab targets the amyloid plaques in the brain that are believed to be an essential component of Alzheimer's disease.
More health and medical news on the Mayo Clinic News Network. https://newsnetwork.mayoclinic.org/
נערך לאחרונה על-ידי dima9000 בתאריך Thu Oct 24, 2019 4:03 am, סך-הכל נערך 4 פעמים